BioTime's OncoCyte raises $10 million to finance cancer therapeutics and diagnostics
This article was originally published in Scrip
Executive Summary
Regenerative medicine company BioTime’s majority-owned subsidiary, OncoCyte Corporation, has received $10 million in a new round of equity financing to fund expansion of its development of proprietary diagnostics and therapeutics for cancer in humans.